Венетоклакс в клинических исследованиях


Т.Е. Бялик

Кафедра онкологии, Первый МГМУ им И.М. Сеченова (Сеченовский Университет), Москва, Россия
Венетоклакс – низкомолекулярный селективный ингибитор белка BCL-2. Препарат высокоэффективен при лечении различных онкогематологических заболеваний. В обзоре приведены данные значимых клинических исследований по изучению эффективности и безопасности венетоклакса. В настоящее время проводятся рандомизированные исследования III фазы по изучению комбинаций VEN с различными противоопухолевыми препаратами при многих заболеваниях кроветворной и лимфоидной тканей, и, возможно, после получения результатов будут изменены подходы к терапии этих болезней.

Литература


1. Seymour J.F., Davids M.S., Pagel J.M., et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti- Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122:872.

2. Roberts A.W., Davids M.S., Pagel J.M., et al. S1146; EHA; Stockholm. 2013;13–6.

3. Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet. Oncol. 2016;17:768–78. Doi: 10.1016/S1470-2045(16)30019-5.

4. Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax for PatientsWith Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol. 2018;36:1–8. Doi: 10.1200/JCO.2017.76.6840

5 Jones J., Choi M.Y., Mato A.R., et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128:abstract 637.

6. Jones J.A., Mato A.R., Wierda W.G., et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;65–75. Doi: 10.1016/S1470-2045(17)30909-9.

7. AbbVie. Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation

8. Eichhorst B., Robak T., Montserrat P., et al. Chronic Lymphocytic Leukaemia Treatment Recommendations, Published: 27 June 2017. Authors: ESMO Guidelines Committee, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(5): 78–84.

9. Seymour J.F., et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia – Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. 59TH Annual meeting and exposition of the american society of hematology. Blood 2017;130:LBA-2.

10. AbbVie’s Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

11. Touzeau C., Dousset C., Le Gouill S., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–12. Doi: 10.1038/leu.2013.216.

12. Kumar S., Kaufman J.L., Gasparetto C., et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401–409. Doi: 10.1182/blood-2017-06-788786.

13. Moreau P., Chanan-Khan A., Roberts A.W., et al. Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2016;128:975. Doi: 10.1182/blood-2017-06-788323.

14. Pan R., Hogdal L.J., Benito J.M., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell. death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–75. Doi: 10.1158/2159-8290.CD-13-0609.

15. Konopleva M., Pollyea D.A., Potluri J., et al. Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106–17.

16. DiNardo C.D., Pratz K.W., Letai A., et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–28. Doi: 10.1016/S1470-2045(18)30010-X.

17. Wei A., Strickland S.A., Roboz G.J., et al. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcome. Blood. 2017;130:890.


Об авторах / Для корреспонденции


Автор для связи: Т.Е. Бялик, ассистент кафедры онкологии, Первый МГМУ им И.М. Сеченова (Сеченовский Университет), Москва, Россия; e-mail:bialik@bk.ru
Адрес: 119991, Россия, Москва, ул. Трубецкая, 8, стр. 2


Похожие статьи


Бионика Медиа